Intercellular cross-talk among bone cells: New factors and pathways

Current Osteoporosis Reports

Volumn 10, Issue 2, 2012, Pages 109-117

  Sims, Natalie A ^a   Walsh, Nicole C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adipocyte; Bone cells; CD100; Coupling; Cross talk; Ephrin; Gp130; IL 33; Lymphocytes; Macrophage; Osteoblast; Osteoclast; Osteocyte; Osteomac; RANKL; Sclerostin; Semaphorin 4D; T reg cells; Tcells

Indexed keywords

EPHRIN; INTERLEUKIN 33; OSTEOCLAST DIFFERENTIATION FACTOR; SCLEROSTIN; SEMAPHORIN; SEMAPHORIN 4D; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; BONE CELL; BONE REMODELING; BONE STRUCTURE; CELL ACTIVITY; CELL COMMUNICATION; CELL DIFFERENTIATION; HUMAN; IMMUNOCOMPETENT CELL; MACROPHAGE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; BONE AND BONES; CELL COMMUNICATION; HUMANS; MODELS, ANIMAL; OSTEOBLASTS; OSTEOCLASTS; RANK LIGAND; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84865765939     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-012-0096-1     Document Type: Article

References (98)

1. Manolagas SC. Cell number versus cell vigor-what really matters to a regenerating skeleton? Endocrinology. 1999;140:4377-81. (Pubitemid 30666098)
2. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 2008;19:444-51.
3. Crockett JC, Rogers MJ, Coxon FP, Hocking LJ, Helfrich MH. Bone remodelling at a glance. J Cell Sci. 2011;124:991-8.
4. Frost HM. Presence of microscopic cracks in vivo in bone. Henry Ford Med Bull. 1960;8:27-35.
5. Tanaka K, Yamaguchi Y, Hakeda Y. Isolated chick osteocytes stimulate formation and bone-resorbing activity of osteoclst-like cells. J Bone Miner Metab. 1995;13:61-70.
6. Verborgt O, Gibson GJ, Schaffler MB. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res. 2000;15:60-7. (Pubitemid 30026933)
7. Noble BS, Stevens H, Loveridge N, Reeve J. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone. 1997;20:273-82. (Pubitemid 27141840)
8. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997;82:3128-35. (Pubitemid 27385687)
9. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5:464-75. (Pubitemid 46825494)
10. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res. 2009;24:597-605.
11. Herman BC, Cardoso L, Majeska RJ, Jepsen KJ, Schaffler MB. Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage. Bone. 2010;47:766-72.
12. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res. 2002;17:2068-79. (Pubitemid 35239208)
13. Al-Dujaili SA, Lau E, Al-Dujaili H, Tsang K, Guenther A, You L. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem. 2011;112:2412-23.
14. Shandala T, Ng YS, Hopwood B, Yip YC, Foster BK, Xian CJ. The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012. doi:10.1002/jcp.23034.
15. Aguirre JI, Plotkin LI, Stewart SA, et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res. 2006;21:605-15.
16. Cheung WY, Liu C, Tonelli-Zasarsky RM, Simmons CA, You L. Osteocyte apoptosis is mechanically regulated and induces angiogenesis in vitro. J Orthop Res. 2011;29:523-30.
17. Cheung WY, Simmons CA, You L. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression. Bone. 2012;50:104-10.
18. Varoga D, Drescher W, Pufe M, Groth G, Pufe T. Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head. Clin Orthop Relat Res. 2009;467:3273-82.
19. Poulton IJ, McGregor NE, Pompolo S, Walker EC, Sims NA. Contrasting roles of LIF in murine bone development and remodeling involve region-specific changes in vascularization. J Bone Miner Res. 2012;27:586-595. doi:10.1002/jbmr.485.
20. Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999;25:525-34. (Pubitemid 29469458)
21. Silvestrini G, Ballanti P, Patacchioli F, et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol. 2005;36:59-67. (Pubitemid 40614383)
22. Mueller RJ, Richards RG Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues. J Mater Sci Mater Med. 2004;15:367-72. (Pubitemid 39012146)
23. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231-4.
24. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17:1235-41.
25. Takahashi N, Akatsu T, Udagawa N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 1988;123:2600-2.
26. Kogianni G, Mann V, Noble BS. Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localised bone destruction. J Bone Miner Res. 2008;23:915-27. (Pubitemid 351768810)
27. Kamioka H, Honjo T, Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone. 2001;28:145-9. (Pubitemid 32140970)
28. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6: e25900.
29. Neuman WF, Neuman MW, Sammon PJ, Casarett GW. The metabolism of labeled parathyroid hormone. IV. Autoradiographic studies. Calcif Tissue Res. 1975;18:263-70.
30. Davideau JL, Papagerakis P, Hotton D, Lezot F, Berdal A. In situ investigation of vitamin D receptor, alkaline phosphatase, and osteocalcin gene expression in oro-facial mineralized tissues. Endocrinology. 1996;137:3577-85. (Pubitemid 26250214)
31. Walker EC, McGregor NE, Poulton IJ, et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010;120:582-92.
32. Gooi JH, Pompolo S, Karsdal MA, et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 2010;46:1486-97.
33. Saleh H, Eeles D, Hodge JM, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. 2011;152:1911-22.
34. Schulze J, Bickert T, Beil FT, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res. 2011;26:704-17.
35. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-58. (Pubitemid 40962421)
36. Keller J, Catala-Lehnen P, Wintges K, et al. Transgenic overexpression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun. 2012;417:217-22.
37. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005;11:76-81. (Pubitemid 40193486)
38. Walker EC, McGregor NE, Poulton IJ, et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008;23:2025-32.
39. Bougeret C, Mansur IG, Dastot H, et al. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J Immunol. 1992;148:318-23.
40. Hall KT, Boumsell L, Schultze JL, et al. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci USA. 1996;93:11780-5. (Pubitemid 26347200)
41. Kumanogoh A, Watanabe C, Lee I, et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000;13:621-31.
42. Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell. 1999;99:71-80. (Pubitemid 29468631)
43. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res. 2004;64:5212-24. (Pubitemid 39006540)
44. Basile JR, Afkhami T, Gutkind JS. Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway. Mol Cell Biol. 2005;25:6889-98. (Pubitemid 41105890)
45. Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17:1473-80.
46. Dacquin R, Domenget C, Kumanogoh A, Kikutani H, Jurdic P, Machuca-Gayet I. Control of bone resorption by semaphorin 4D is dependent on ovarian function. PLoS One. 2011;6:e26627.
47. Shi W, Kumanogoh A, Watanabe C, et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity. 2000;13:633-42.
48. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrin B2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4:111-21. (Pubitemid 44138718)
49. Wang Z, Cohen K, Shao Y, Mole P, Dombkowski D, Scadden DT Ephrin receptor, EphB4, regulates ES cell differentiation of primitive mammalian hemangioblasts, blood, cardiomyocytes, and bloodvessels. Blood. 2004;103:100-9. (Pubitemid 38029924)
50. Taylor AC, Murfee WL, Peirce SM. EphB4 expression along adult rat microvascular networks: EphB4 is more than a venous specific marker. Microcirculation. 2007;14:253-67. (Pubitemid 46547102)
51. Wang Y, Nakayama M, Pitulescu ME, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010;465:483-6.
52. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell. 1999;4:403-14. (Pubitemid 29499793)
53. Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009;174:239-47.
54. Martin TJ, Sims NA, Quinn JMW. Interactions among osteoblasts, osteoclasts, and other cells in bone. In: Lorenzo J, Choi YW, Horowitz MC, Takayanagi H, editors. Osteoimmunology: interactions of the immune and skeletal systems. London: Academic; 2010. p. 227-68.
55. Yu G, Mao J, Wu Y, Luo H, Wu J. Ephrin-B1 is critical in T-cell development. J Biol Chem. 2006;281:10222-9. (Pubitemid 43864559)
56. Allan EH, Hausler KD, Wei T, et al. Ephrin B2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res. 2008;23:1170-81. (Pubitemid 352040173)
57. Arthur A, Zannettino A, Panagopoulos R, et al. EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone. 2011;48:533-42.
58. Martin TJ, Allan EH, Ho PW, et al. Communication between Ephrin B2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol. 2010;658:51-60.
59. Xing W, Kim J, Wergedal J, Chen ST, Mohan S. Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. Mol Cell Biol. 2010;30:711-21.
60. Davy A, Aubin J, Soriano P. Ephrin-B1 forward and reverse signaling are required during mouse development. Genes Dev. 2004;18:572-83. (Pubitemid 38372813)
61. Compagni A, Logan M, Klein R, Adams RH. Control of skeletal patterning by ephrin B1-EphB interactions. Dev Cell. 2003;5:217-30. (Pubitemid 37006467)
62. Ting MC, Wu NL, Roybal PG, et al. EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis. Development. 2009;136:855-64.
63. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-43. (Pubitemid 32184286)
64. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15:928-35. (Pubitemid 40994212)
65. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-89. (Pubitemid 32202753)
66. Zhu D, Mackenzie NC, Millan JL, Farquharson C, Macrae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One. 2011;6:e19595.
67. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-76. (Pubitemid 37522584)
68. Chan BY, Fuller ES, Russell AK, et al. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthr Cartil. 2011;19:874-85.
69. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics. 2010;9:2048-62.
70. Sims NA, Chia LY Regulation of sclerostin expression by paracrine and endocrine factors. Clin Rev Bone Miner Metab. 2012. doi:10.1007/s12018-011-9121- 7.
71. Genetos DC, Yellowley CE, Loots GG. Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression. PLoS One. 2011;6:e17772.
72. Mantila Roosa SM, Liu Y, Turner CH. Gene expression patterns in bone following mechanical loading. J Bone Miner Res. 2011;26:100-12.
73. Takada I, Kouzmenko AP, Kato S. Molecular switching of osteo-blastogenesis versus adipogenesis: implications for targeted therapies. Expert Opin Ther Targets. 2009;13:593-603.
74. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol. 2009;5:365-72.
75. Kelly KA, Tanaka S, Baron R, Gimble JM. Murine bone marrow stromally derived BMS2 adipocytes support differentiation and function of osteoclast-like cells in vitro. Endocrinology. 1998;139:2092-101. (Pubitemid 28513873)
76. Quach JM, Walker EC, Allan E, et al. Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. J Biol Chem. 2011;286:4186-98.
77. Goto H, Osaki M, Fukushima T, et al. Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression. Biomed Res. 2011;32:37-44.
78. Goto H, Hozumi A, Osaki M, et al. Primary human bone marrow adipocytes support TNF-alpha-induced osteoclast differentiation and function through RANKL expression. Cytokine. 2011;56:662-8.
79. Kuhn MC, Willenberg HS, Schott M, et al. Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation. Mol Cell Endocrinol. 2012;349:180-8.
80. Quinn JM, Saleh H. Modulation of osteoclast function in bone by the immune system. Mol Cell Endocrinol. 2009;310:40-51.
81. Okamoto K, Takayanagi H. Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther. 2011;13:219.
82. Oostlander AE, Everts V, Schoenmaker T, et al. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for crohn's disease-associated bone loss. J Cell Biochem. 2012;113:260-8.
83. Won HY, Lee JA, Park ZS, et al. Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice. PLoS One. 2011;6:e18168.
84. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012
85. Kim YG, Lee CK, Nah SS, Mun SH, Yoo B, Moon HB. Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2007;357:1046-52. (Pubitemid 46693677)
86. Kelchtermans H, Geboes L, Mitera T, Huskens D, Leclercq G, Matthys P. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann Rheum Dis. 2009;68:744-50.
87. Zaiss MM, Axmann R, Zwerina J, et al. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007;56:4104-12. (Pubitemid 350262338)
88. Zaiss MM, Sarter K, Hess A, et al. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum. 2010;62:2328-38.
89. Zaiss MM, Frey B, Hess A, et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol. 2010;184:7238-46.
90. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-9.
91. Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70:1826-30.
92. Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 2008;181:1232-44.
93. Pettit AR, Chang MK, Hume DA, Raggatt LJ. Osteal macrophages: a new twist on coupling during bone dynamics. Bone. 2008;43:976-82.
94. Alexander KA, Chang MK, Maylin ER, et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res. 2011;26:1517-32.
95. Levesque JP, Winkler IG. Mobilization of hematopoietic stem cells: state of the art. Curr Opin Organ Transplant. 2008;13:53-8.
96. Christopher MJ, Link DC. Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation. J Bone Miner Res. 2008;23:1765-74.
97. Winkler IG, Sims NA, Pettit AR, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood. 2010;116:4815-28.
98. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med. 2011;208:251-60.